Cancer clinical trials in the Philippines.


Journal

Cancer causes & control : CCC
ISSN: 1573-7225
Titre abrégé: Cancer Causes Control
Pays: Netherlands
ID NLM: 9100846

Informations de publication

Date de publication:
Oct 2022
Historique:
received: 09 02 2022
accepted: 22 06 2022
pubmed: 21 7 2022
medline: 2 9 2022
entrez: 20 7 2022
Statut: ppublish

Résumé

In this Commentary, we discuss disparities in resources for and access to cancer trials from the perspective of the Philippines, a lower-middle-income country in Southeast Asia, where cancer is the fourth leading cause of death. Geographic disparities play out such that academic institutions and clinical trials are centralized in the island of Luzon, particularly in the capital, Manila. These disparities are compounded by the lack of comprehensive cancer patient and clinical trial registries in the Philippines. Additionally, sociocultural considerations influence clinical trial implementation. Providers must consider the role of a patient's family in the decision to participate in clinical trials; a patient's degree of health literacy; and the economic burden of cancer care, with attention to both the direct and indirect financial toxicities associated with cancer care. Our call to action is threefold. (1) Bolster locally led trials and encourage international collaboration to improve diversity in trial participation and trials' generalizability. (2) Strengthen national trial registries to improve awareness of trials for which patients are eligible. (3) Integrate cultural competency frameworks that move beyond parachutism and parasitism in research and instead promote trust, reciprocity, and collaboration. These challenges may yet evolve, but in emphasizing these barriers, we hope to kindle further dialogue, new insights, and innovative action towards solving these disparities in cancer research, not just in the Philippines, but also in other low- and middle-income countries.

Identifiants

pubmed: 35857181
doi: 10.1007/s10552-022-01611-9
pii: 10.1007/s10552-022-01611-9
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1273-1275

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Références

Philippine Statistics Authority (2022) Causes of deaths in the Philippines (Preliminary): January to October 2021. https://psa.gov.ph/content/causes-deaths-philippines-preliminary-january-october-2021 . Accessed 29 Jan 2022
Dayrit M, Lagrada L, Picazo O, Pons M, Villaverde M (2018) The Philippines health system review. World Health Organization. Regional Office for South-East Asia. https://apps.who.int/iris/handle/10665/274579 . Accessed 7 Nov 2021
Flores L (2020) Hospitals in the Philippines: where they are—and aren’t. Rappler. https://www.rappler.com/newsbreak/in-depth/locations-mapping-hospitals-healthcare-facilities-philippines/ . Accessed 31 Jan 2022
Esteban D, Laudico A, Uy N, Benabay L (2001) Cancer registration in the Philippines. Asian Pac J Cancer Prev 2:55–60
Nipp RD, Hong K, Paskett ED (2019) Overcoming barriers to clinical trial enrollment. Am Soc Clin Oncol Educ Book 39:105–114. https://doi.org/10.1200/EDBK_243729
doi: 10.1200/EDBK_243729 pubmed: 31099636
Nipp RD, Lee H, Powell E et al (2016) Financial burden of cancer clinical trial participation and the impact of a cancer care equity program. Oncologist 21(4):467–474. https://doi.org/10.1634/theoncologist.2015-0481
doi: 10.1634/theoncologist.2015-0481 pubmed: 26975867 pmcid: 4828126
Franzen SRP, Chandler C, Siribaddana S, Atashili J, Angus B, Lang T (2017) Strategies for developing sustainable health research capacity in low and middle-income countries: a prospective, qualitative study investigating the barriers and enablers to locally led clinical trial conduct in Ethiopia, Cameroon and Sri Lanka. BMJ Open 7(10):e017246. https://doi.org/10.1136/bmjopen-2017-017246
doi: 10.1136/bmjopen-2017-017246 pubmed: 29030412 pmcid: 5652508
Wallington SF, Dash C, Sheppard VB et al (2016) Enrolling minority and underserved populations in cancer clinical research. Am J Prev Med 50(1):111–117. https://doi.org/10.1016/j.amepre.2015.07.036
doi: 10.1016/j.amepre.2015.07.036 pubmed: 26470805
Smith J (2018) Parasitic and parachute research in global health. Lancet Glob Health 6(8):e838. https://doi.org/10.1016/S2214-109X(18)30315-2
doi: 10.1016/S2214-109X(18)30315-2 pubmed: 30012263
Congress of the Philippines (2019) National Integrated Cancer Control Act. https://www.officialgazette.gov.ph/downloads/2019/02feb/20190214-RA-11215-RRD.pdf . Accessed 7 Feb 2022

Auteurs

Michelle Ann B Eala (MAB)

College of Medicine, University of the Philippines, 547 Pedro Gil Street, 1000, Manila, Philippines. mbeala1@up.edu.ph.

Patricia Anne S Basilio (PAS)

College of Medicine, University of the Philippines, 547 Pedro Gil Street, 1000, Manila, Philippines.

Edward Christopher Dee (EC)

Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Reno Eufemon P Cereno (REP)

Department of Radiation Oncology, British Columbia Cancer Agency, Kelowna, BC, Canada.

Christian Daniel Ang (CD)

Department of Surgical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Surgery, University of Santo Tomas Faculty of Medicine and Surgery, Manila, Philippines.

Nikko J Magsanoc (NJ)

Division of Urology, Department of Surgery, Philippine General Hospital, Manila, Philippines.

Frederic Ivan L Ting (FIL)

Section of Medical Oncology, Department of Internal Medicine, Dr. Pablo O. Torre Memorial Hospital, Bacolod, Philippines.

Dennis L Sacdalan (DL)

Division of Medical Oncology, Department of Internal Medicine, Philippine General Hospital, Manila, Philippines.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH